The BRAF inhibitor, vemurafenib, is associated with photosensitivity. This small study identifies ultraviolet A (UVA) as the active agent. UVA blockers may be effective in preventing photosensitivity among patients taking vemurafenib.
No takes yet. Share an insight, caveat, or question.
Dummer et al. (2012) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: